USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Loewenstein Medical Technology S.A.

USPTO PatentsView assignee record - 77 granted patents across 24 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

RSS updates for this company

The verdict

According to USPTO PatentsView, Loewenstein ranks #4,568 of 49,997 tracked US assignees by granted-patent volume, with 77 patents across 24 technology areas.

#4,568
of 49,997 US assignees by volume
Top 4%
by Innovation Score (58.6/100)
19.0
avg claims per patent
+300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4568 · Foreign Corporation #4,568 · 77 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 77 grants
  • TOP-DECILE #4,568/49,997
  • PHOTO-FINISH Idorsia Pharmaceutic…
  • CPC-FOCUS A61M · 24 areas
  • INNOV-PAR 58.6/100
  • CLAIMS-RICH 19.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Idorsia Pharmaceuticals Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Loewenstein

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Loewenstein's Innovation Score is 58.6/100 (top 4% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Loewenstein's grants concentrate

Loewenstein Medical Technology S.A. is a focused PatentsView assignee: 24 CPC subclasses with 94.8% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (15 grants) versus a trough of 3 in 2017. By volume, Loewenstein sits between Idorsia Pharmaceuticals Ltd and Mie Fujitsu Semiconductor Limited.

Loewenstein's three-year grant acceleration

Loewenstein Medical Technology S.A. shows 40 grants in 2022–2024 against only 18 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Loewenstein's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Loewenstein holds 77 patents at rank #4,567, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Loewenstein

By rank, the assignees closest to #4,567 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Loewenstein's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Loewenstein, neither rank-band nor same-CPC leaders (those blocks stay above).

Loewenstein's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

05101520 201720182019202020212022202320242025 12
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Loewenstein Medical Technology S.A. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 3 3.9%
2018 4 5.2%
2019 6 7.8%
2020 4 5.2%
2021 8 10.4%
2022 11 14.3%
2023 14 18.2%
2024 15 19.5%
2025partial year 12 15.6%

Where it ranks

Overall rank by patents

#4,568

of 49,997 tracked assignees

Innovation Score

58.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Loewenstein Medical Technology S.A.'s patent record in context - here's where to go next.

  • Loewenstein Medical Technology S.A.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 94.8% of its portfolio - see every assignee active in that class. Explore A61M
  • Ranked #4,568 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Loewenstein Medical Technology S.A. against Idorsia Pharmaceuticals Ltd, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 58.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.